Fc Variant Antibodies Modulating Receptor Clustering and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies have limitations in their effector functions, such as binding to Fc receptors and complement-dependent cytotoxicity, which can lead to unwanted toxicity and reduced therapeutic efficacy.
Innovation Solution
Engineering polypeptides with variants of the Fc region of human IgG, incorporating specific amino acid substitutions, to alter effector function, reduce affinity to human Fc receptors, and enhance receptor clustering, while decreasing complement-dependent cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies bind to Fc receptors to exert effector functions, then therapeutic efficacy is improved, but unwanted toxicity increases
Solution Approach 1:
The patent applies local quality by making different parts of the Fc region have different binding affinities to different Fc receptor subtypes. Specific amino acid substitutions (e.g., at positions 234-235, 345, 409, 430) create localized variations in binding characteristics, allowing the antibody to selectively bind to certain Fc receptors while avoiding others, thereby achieving therapeutic efficacy without unwanted toxicity.
Solution Approach 2:
The patent changes the binding affinity parameter of the Fc region through amino acid substitutions. By modifying residues at specific positions (such as E345K, E430G, L234A, L235A), the antibody's interaction strength with Fc receptors is altered, enabling controlled engagement with desired receptors while reducing binding to harmful targets.
2Reliability
If monoclonal antibodies engage Fc receptors to mediate complement-dependent cytotoxicity, then therapeutic effect is enhanced, but complement-dependent cytotoxicity increases causing damage
Solution Approach 1:
The patent creates local quality differences in the Fc region that selectively modulate complement activation. Amino acid substitutions at specific positions (such as D270A, K322A, P329V, P331V, E333Q) locally alter the Fc region's interaction with complement components, enabling therapeutic engagement while preventing excessive complement activation and cytotoxicity.
Solution Approach 2:
The patent changes the complement activation parameter by introducing amino acid substitutions that modify the Fc region's structural and interaction properties. These substitutions (e.g., at positions 270, 322, 329, 331, 333) alter the affinity and orientation of complement binding, reducing harmful cytotoxic effects while preserving therapeutic mechanisms.
3Reliability
If Fc region has high affinity to Fc receptors, then effector function is strong, but receptor clustering is reduced
Solution Approach 1:
The patent applies local quality by creating spatially distinct binding characteristics within the Fc region. Amino acid substitutions at different positions (e.g., 234-235 vs. 345 vs. 409) create localized binding hotspots that simultaneously engage Fc receptors and promote receptor clustering, resolving the contradiction between strong effector function and reduced clustering.
Solution Approach 2:
The patent resolves the contradiction by transitioning from a single-dimension binding model to a multi-dimensional interaction framework. Multiple amino acid substitutions create a distributed binding pattern across different spatial and functional dimensions of the Fc region, enabling simultaneous high-affinity binding and receptor clustering through coordinated interactions at multiple sites.
Data Source
AI summary
The present invention provides compositions and methods for augmenting antibody mediate receptor signaling.